Arvinas: FDA approval for VEPPANU serves as revenue and earnings driver - Two analyst firms see 122% price potential each!

Arvinas (ARVN) is currently in the spotlight for investors and analysts. The business model is based on targeted protein degradation (PROTAC) to selectively eliminate disease-causing proteins in oncology and neurology. Due to one-off effects and licensing agreements related to the VEPPANU approval, the company reported earnings of $2.58 per share for the second quarter of 2026. With liquid assets of $567.9 million, operations are secured until the end of 2028, with a future focus on cost-optimized development of the core pipeline. On August 5,...